Evidence map›Paper›PMID 28951581›Full record

ReviewNature reviews. Gastroenterology & hepatology2017

Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.

Steven Naymagon, Leonard Naymagon, Serre-Yu Wong, Huaibin Mabel Ko, Anne Renteria, John Levine, Jean-Frederic Colombel, James Ferrara

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Radiology. Imaging cancer · 2025
    Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Steven NaymagonHenry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai One Gustave Levy Place, New York, New York 10029, USA.
Leonard NaymagonDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai One Gustave Levy Place, New York, New York 10029, USA.
Serre-Yu WongHenry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai One Gustave Levy Place, New York, New York 10029, USA.
Huaibin Mabel KoHenry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai One Gustave Levy Place, New York, New York 10029, USA.
Anne RenteriaDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai One Gustave Levy Place, New York, New York 10029, USA.
John LevineDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai One Gustave Levy Place, New York, New York 10029, USA.
Jean-Frederic ColombelHenry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai One Gustave Levy Place, New York, New York 10029, USA.
James FerraraDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai One Gustave Levy Place, New York, New York 10029, USA.

Funding

TUMOR VACCINES AND BONE MARROW TRANSPLANTATIONP01CA039542 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAVAN REDDY · 1985 to 2026
$47.9M
NCI NIH HHS P01 CA039542
6 · The paper itself

Abstract

Haematopoietic stem cell transplantation (HSCT) is central to the management of many haematological disorders. A frequent complication of HSCT is acute graft-versus-host disease (GVHD), a condition in which immune cells from the donor attack healthy recipient tissues. The gastrointestinal system is among the most common sites affected by acute GVHD, and severe manifestations of acute GVHD of the gut portends a poor prognosis in patients after HSCT. Acute GVHD of the gastrointestinal tract presents both diagnostic and therapeutic challenges. Although the clinical manifestations are nonspecific and overlap with those of infection and drug toxicity, diagnosis is ultimately based on clinical criteria. As reliable serum biomarkers have not yet been validated outside of clinical trials, endoscopic and histopathological evaluation continue to be utilized in diagnosis. Once a diagnosis of gastrointestinal acute GVHD is established, therapy with systemic corticosteroids is typically initiated, and non-responders can be treated with a wide range of second-line therapies. In addition to treating the underlying disease, the management of complications including profuse diarrhoea, severe malnutrition and gastrointestinal bleeding is paramount. In this Review, we discuss strategies for the diagnosis and management of acute GVHD of the gastrointestinal tract as they pertain to the practising gastroenterologist.

Indexed as

Acute DiseaseDiagnosis, DifferentialGastrointestinal DiseasesGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumans

Identifiers

PMID28951581
PMCPMC6240460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.